Optional callout banner for highlighted news or events

Learn More
Contact Us

Artful Taste Masking Improves Patient Compliance

By: Sundeep Sethia, Ph.D., Head of R&D

The flavor taste masking market is expected to jump from $224 million in 2021 to $331 million by 2028.1 One driver behind this increase comes from the pharma industry. According to a recent webinar, Solving the Taste-masking Challenge, more than 90 percent of pediatricians report that a drug’s taste and palatability are the biggest barriers to completing treatment and 11 percent of adverse events relate to abnormal taste or poor aftertaste.

Taste Masking is required for dosage form that interact with the taste buds, such as solutions, suspensions, powders, films, chewable tablets, and orally disintegrating tablets – the preferred dosage forms for pediatric and geriatric populations. Traditional coated tablets, capsules, and soft gels interact minimally with the taste buds as they are swallowed, hence most drugs in these dosage forms do not require taste masking. The best and most practical method of taste masking should be considered for each API. Some of these methods are discussed below.

Sweeteners & Flavoring Agents

Flavors and sweeteners (natural or synthetic) are the most common and easiest ways to mask taste, especially in liquid formulas and chewable tablets. Natural sweeteners include sucrose, glucose, fructose, sorbitol, mannitol, glycerol, honey, and liquor ice. Artificial sweeteners include saccharin, saccharin sodium, aspartame, and sucralose. Sweeteners promote a cooling sensation on the esophageal surface, Note: This method is not very effective for very bitter and water-soluble drugs.

Lipids

Complexation and Inclusion Complexation

Coatings & Granulation

Emulsions

Tips for Choosing a Taste Masking Method

Talk to a Pii Scientist

Contact

ABOUT Pii

Pharmaceutics International, Inc. (Pii), A Jabil Company, is a US-based contract development and manufacturing organization (CDMO) located in Hunt Valley, Maryland. The experienced scientists, engineers, and staff at Pii pride themselves on adroitly employing a phase appropriate method of drug development for the prudent use of their customer’s resources as they solve challenging problems. In addition to offering end-to-end development services, Pii manufactures a variety of dosage forms to include complex parenteral drugs and has a wealth of analytical testing capabilities. Its Hunt Valley campus has four aseptic suites with lyophilization capabilities. Our talented professionals stand ready to help!

Sundeep Sethia, Ph.D.
Vice President, R&D

Sundeep Sethia joined Pii in September 2018 as Senior Director of Pharmaceutical R&D. He has over 15 years of experience in the pharmaceutical industry.

Dr. Sethia formerly served as the Director of Pharmaceutical R&D at Amneal Pharmaceuticals. Prior to Amneal, he held positions of increasing responsibility at both Teva and Barr Laboratories in R&D. His expertise is in drug development across a broad range of therapeutic areas and dosage forms. He has a proven track record in generic drug development and approvals.

Dr. Sethia received his Ph.D. in Pharmaceutical Sciences from St. John’s University, NY. He earned a Master’s and a Bachelor’s degree in Biotechnology and Pharmacy, respectively from Jadavpur University in India. He has co-authored various peer-reviewed scientific publications and patents/patent applications.

Follow Dr. Sundeep Sethia, Ph.D.

Like what you read? Share with your network:

crossmenu